Abstract 40P
Background
Camptothecins are effective agents that selectively target topoisomerase I and are widely used as payload in ADC. Myelosuppression is the most common toxicity of camptothecins and ADC. Clinical experience suggests ADC toxicities are primarily driven by payload in a target-independent mechanism. Thus, we hypothesized that a “soft drug” design of camptothecin would result in a set of new payloads that possess potent anti-tumor activities and reduced toxicity. ADCs built from such soft topoisomerase inhibitors may exhibit improved safety to overcome these dose-limiting toxicities.
Methods
Camptothecin was structurally modified to maintain potent in vitro cytotoxicity, and meanwhile, minimize its exposure in circulation to reduce toxicity. We next constituted a Her2 ADC (T-PL1), which was composed of Trastuzumab conjugated to new payload PL1 at a DAR ratio of 8, with the same linker as DS-8201 (T-DXd). PL1 and T-PL1 were evaluated in multiple preclinical studies using standard methodology, in comparison with Dxd and DS-8201.
Results
In vitro studies demonstrated that new camptothecin PL1 had comparable cytotoxicity to Dxd across a panel of tumor cell lines. A rat pharmacokinetic study demonstrated that PL1 was quickly cleared from circulation resulting in low systemic exposure. In a 3-week intermittent toxicity study in rat, Dxd treatment at 3 mg/kg resulted in reduction of lymphocyte, neutrophil, platelet, and white blood cell counts. In contrast, PL1 treatment at 10 mg/kg had no effect on these hematological indices. Its ADC T-PL1 possessed comparable anti-tumor activities to DS-8201, moreover, it also exhibited robust tumor suppression in CDX models. Importantly, in a rat toxicity study, DS-8201 treatment at 60 mg/kg caused decreases in lymphocyte and white blood cell counts, while T-PL1 outperformed it and showed no trend of hematological toxicity at the same dosage.
Conclusions
The STOPIN design not only generated a new camptothecin with great potency and reduced hematological toxicity, but also provided a new ADC exhibiting excellent anti-tumor efficacy and improved safety as compared to DS-8201. This unique feature may provide a new approach to widen the ADC therapeutic window. Further preclinical evaluation of STOPIN-based ADC candidates is underway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shanghai MicuRx Pharmaceutical Co., Ltd.
Funding
Shanghai MicuRx Pharmaceutical Co., Ltd.
Disclosure
X. Wang, H. Yang, Y. Li, L. Wang, S. Liu: Financial Interests, Personal, Full or part-time Employment: MicuRx.
Resources from the same session
31P - Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors
Presenter: Li Lin
Session: Poster session 07
32P - Patient derived circulating tumor cell clusters for personalized chemotherapy
Presenter: Prashant Kumar
Session: Poster session 07
Resources:
Abstract
33P - Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors
Presenter: Noémie Luong
Session: Poster session 07
34P - A novel gene family underlying cancer cell resilience
Presenter: David Amici
Session: Poster session 07
35P - The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
Presenter: Jianhui Ma
Session: Poster session 07
36P - Branched-chain amino acids metabolism reprogramming in trastuzumab primary resistant HER2 positive breast cancer
Presenter: Yijia Hua
Session: Poster session 07
37P - A consensus gene set facilitates enrichment analysis of cancer hallmarks
Presenter: Otília Menyhart
Session: Poster session 07
38P - Feasibility of expanding tumor-infiltrating lymphocytes from cryopreserved tumor specimens after long-term storage
Presenter: Daria Kuznetsova
Session: Poster session 07
39P - Search for rare copy number variants associated with hereditary breast cancer in Finnish case-control cohorts
Presenter: Timo Kumpula
Session: Poster session 07
41P - Cancer therapy-related cardiac dysfunction (CTRCD) after radiation therapy for breast cancer: Results of the French BACCARAT study
Presenter: Manoj Kumar Francois HONARYAR
Session: Poster session 07
Resources:
Abstract